Author(s): Lenaerts AJ, Bitting C, Woolhiser L, Gruppo V, Marietta KS,
Abstract Share this page
Abstract A novel subclass of quinolones, 2-pyridones, showed potent activity against Mycobacterium tuberculosis, with KRQ-10018 being an early lead. KRQ-10018 showed better activity in vitro against M. tuberculosis versus moxifloxacin. In vivo efficacy of KRQ-10018 at 300 mg/kg of body weight was similar to that of isoniazid at 25 mg/kg, but showed less activity than moxifloxacin at 300 mg/kg.
This article was published in Antimicrob Agents Chemother
and referenced in Journal of Antivirals & Antiretrovirals